Effectiveness And Safety Of A New Vaginal Misoprostol Product Specifically Labeled For Cervical Ripening And Labor Induction.

dc.creatorCecatti, José Guilherme
dc.creatorTedesco, Ricardo Porto
dc.creatorPires, Helaine Maria Besteti
dc.creatorCalderon, Iracema Matos
dc.creatorFaúndes, Aníbal
dc.date2006
dc.date2015-11-27T13:05:30Z
dc.date2015-11-27T13:05:30Z
dc.date.accessioned2018-03-29T01:02:55Z
dc.date.available2018-03-29T01:02:55Z
dc.identifierActa Obstetricia Et Gynecologica Scandinavica. v. 85, n. 6, p. 706-11, 2006.
dc.identifier0001-6349
dc.identifier10.1080/00016340500432580
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/16752263
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/196797
dc.identifier16752263
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1297030
dc.descriptionThe purpose of this study was to evaluate the effectiveness and safety of misoprostol in two different formulations: vaginal tablets of 25 microg and one-eighth of a 200-microg oral tablet, also administered intravaginally, for cervical ripening and labor induction of term pregnancies with an indication for that. A single-blind, randomized, controlled clinical trial was carried out in 120 pregnant women who randomly received one of the two formulations. The main dependent variables were mode of delivery, need for additional oxytocin, time between beginning of induction and delivery, perinatal results, complications, and maternal side effects. Student's t, Mann-Whitney, chi2, Fisher's Exact, Wilcoxon and Kolmogorov-Smirnoff tests, as well as survival analysis, were used in the data analysis. There were no significant differences between the groups in terms of general characteristics, uterine contractility, and fetal well-being during labor, cesarean section rates, perinatal outcomes, or maternal adverse events. The mean time between the beginning of cervical ripening and delivery was 31.3 h in the vaginal tablet group and 30.1 h in the oral tablet group, a difference that was not statistically significant. The results showed that the 25-microg vaginal tablets of misoprostol were as effective and safe for cervical ripening and labor induction as the dose-equivalent fraction of 200-microg oral tablets.
dc.description85
dc.description706-11
dc.languageeng
dc.relationActa Obstetricia Et Gynecologica Scandinavica
dc.relationActa Obstet Gynecol Scand
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdministration, Intravaginal
dc.subjectAdult
dc.subjectCervical Ripening
dc.subjectCervix Uteri
dc.subjectFemale
dc.subjectHumans
dc.subjectLabor, Induced
dc.subjectMisoprostol
dc.subjectOxytocics
dc.subjectPilot Projects
dc.subjectPregnancy
dc.subjectPregnancy Outcome
dc.subjectSingle-blind Method
dc.subjectTreatment Outcome
dc.titleEffectiveness And Safety Of A New Vaginal Misoprostol Product Specifically Labeled For Cervical Ripening And Labor Induction.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución